Supreme Showdown: Abortion Pill Takes Center Stage
The U.S. Supreme Court upheld a federal rule on the abortion pill mifepristone, allowing it to be prescribed via telemedicine and mail, despite challenges led by Louisiana. This decision is amid ongoing legal battles over abortion rights following the overturning of Roe v. Wade in 2022.
The U.S. Supreme Court on Thursday ruled in favor of maintaining access to the abortion pill mifepristone through telemedicine and mail, a move counteracting a Louisiana-led challenge to a 2023 federal rule.
Key pharmaceutical companies, Danco Laboratories and GenBioPro, successfully appealed yet another restriction set by the New Orleans-based 5th U.S. Circuit Court of Appeals.
The contentious issue comes on the heels of the Court's pivotal 2022 decision in Dobbs v. Jackson Women's Health Organization, which dissolved nearly half a century of established abortion rights and ignited legal maneuvers nationwide.
ALSO READ
-
Supreme Court Maintains Access to Abortion Drug Amid Legal Battle
-
Telehealth Transformation: Supreme Court Upholds Mail-Order Mifepristone Rule
-
Supreme Court Upholds Telemedicine Access for Abortion Pill Amid Legal Challenges
-
Supreme Court Upholds Access to Abortion Pill Amid Ongoing Legal Battle
-
Supreme Court Greenlights Telemedicine Abortion Pill Amid Legal Turmoil
Google News